Inactive Instrument

Company GRI Bio, Inc.

Equities

GRI

US3622AW2059

End-of-day quote Nasdaq Other stock markets 18:00:00 2024-05-14 EDT			5-day change	1st Jan Change
0.4007 ^USD	-1.18%		+2.72%	-85.13%

05-21	GRI Bio, Inc Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus	CI
05-20	GRI Bio, Inc. Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis	CI

Business Summary

GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. Its lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as an oral therapeutic for the treatment of idiopathic pulmonary fibrosis (IPF). Its product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. The Company is developing GRI-0803 for the treatment of autoimmune disorders, with much of its preclinical work in systemic lupus erythematosus disease (SLE) or lupus and multiple sclerosis (MS).

Number of employees: 4

Managers

Managers	Title	Age	Since
W. Hertz CEO	Chief Executive Officer	54	23-03-31
Leanne Kelly DFI	Director of Finance/CFO	47	23-04-24
Vipin Kumar Chaturvedi CTO	Chief Tech/Sci/R&D Officer	64	23-03-31
Albert Agro CTO	Chief Tech/Sci/R&D Officer	59	23-03-31

Members of the board

Members of the board	Title	Age	Since
David Baker BRD	Director/Board Member	60	-
Roelof Rongen BRD	Director/Board Member	59	23-04-23
David Szekeres CHM	Chairman	50	23-04-23
W. Hertz CEO	Chief Executive Officer	54	23-03-31
Camilla Simpson BRD	Director/Board Member	52	23-04-23

Shareholders

Name	Equities	%	Valuation
Altium Capital Management LP 4.980 %	187,981	4.980 %	56 770 $
W. Hertz 1.459 %	55,072	1.459 %	16 632 $
HRT Financial LLC 0.5169 %	19,509	0.5169 %	5 892 $
Two Sigma Securities LLC 0.3365 %	12,701	0.3365 %	3 836 $
UBS Securities LLC 0.2125 %	8,021	0.2125 %	2 422 $
Tower Research Capital LLC 0.1597 %	6,027	0.1597 %	1 820 $
Albert Agro 0.0217 %	820	0.0217 %	248 $
Vipin Kumar Chaturvedi 0.0217 %	820	0.0217 %	248 $
David Baker 0.001113 %	42	0.001113 %	13 $
Leanne Kelly 0.000768 %	29	0.000768 %	9 $

Company contact information

GRI Bio, Inc.

2223 Avenida De La Playa Suite 208

92037, La Jolla

http://www.gribio.com

Sector

This company's sector is not yet available